AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06119607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRIFLO Heart Valve
Description: Surgical Aortic Valve Replacement - Mechanical Valve
Study NCT06547125 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: JUVÉDERM® VOLITE™
Description: Injection, intradermal
Study NCT06547125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM® VOLITE™
Description: Injection, intradermal
Study NCT06547125 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No-treatment control
Study NCT04696354 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: IVUS
Description: Those who are randomized to the interrogation arm will have diagnostic imaging performed by IVUS to determine their treatment plan.
Study NCT04696354 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Continued Compression Therapy/Stockings
Description: Those who are randomized to the deferred interrogation arm while continue compression therapy as prescribed.
Study NCT04991077 — intervention group
Intervention type: BIOLOGICAL
Intervention: analyse of angiogenic, vasoactive and VEGF systems
Description: the angiogenic, vasoactive and VEGF systems will be analysed through blood and urine sampling. These samples will be collected at the time of malignant hypertension diagnosis and repeated one month later, in 30 patients (patients group). The same tests will be performed once in 15 patients with severe non-malignant hypertension, constituting the control group.
Study NCT06474988 — intervention group
Intervention type: OTHER
Intervention: Skin tests
Description: Acquisition of Skindex questionnaire 29 and execution of instrumental skin tests
Study NCT05892276 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma Memory Reactivation
Description: Participants will be guided through the trauma memory reactivation paradigm by the study staff. The trauma memory reactivation paradigm entails two distinct procedures: (1) participants will watch a video clip related to their trauma; then (2) describe a verbal narrative of their traumatic event for approximately 5 minutes to a research team member.
Study NCT05892276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Memory Reactivation
Description: Participants will be guided through the trauma memory reactivation paradigm by the study staff. The trauma memory reactivation paradigm entails two distinct procedures: (1) participants will watch a video clip related to their trauma; then (2) describe a verbal narrative of their traumatic event for approximately 5 minutes to a research team member.
Study NCT05772975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H-PRF (Horizontal-platelet rich fibrin)
Description: Platelet-rich fibrin is an autologous biomaterial originating from human blood following centrifugation without additives that contains supraphysiological doses of growth factors. it serves as a biological healing matrix by supporting cell migration and cytokine release. H-PRF is obtained by horizontal centrifugation using (Bio-PRF) centrifuge on 700 g force for 8 minutes. This way the cells separate much more efficiently throughout the entire membrane/clot.
Study NCT05892276 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Trauma Memory Reactivation
Description: Participants will be guided through the trauma memory reactivation paradigm by the study staff. The trauma memory reactivation paradigm entails two distinct procedures: (1) participants will watch a video clip related to their trauma; then (2) describe a verbal narrative of their traumatic event for approximately 5 minutes to a research team member.
Study NCT05892276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) Broad-Spectrum Oil
Description: 300mg CBD broad-spectrum oil.
Study NCT05892276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) Broad-Spectrum Oil
Description: 300mg CBD broad-spectrum oil.
Study NCT05892276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oil
Description: 3ml oral dose of medium-chain triglycerides (MCT) coconut oil.
Study NCT06458036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib Monotherapy
Description: Patients will receive selpercatinib monotherapy for 6 months at the FDA-approved dose.
Study NCT06458036 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131I Therapy
Description: Patients will receive 131I therapy after 6 months of selpercatinib.
Study NCT06575972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: JoyRise Recovery Powder
Description: JoyRise Recovery Powder is a dietary supplement that contains Dihydromyricetin (DHM) and other natural ingredients. It is designed to mitigate the aftereffects of alcohol consumption. Participants will mix one serving in 8-12 oz of water and consume it the morning after alcohol consumption.
Study NCT06575972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo solution that is visually and tastefully similar to JoyRise Recovery Powder but contains no active ingredients. It will be mixed in 8-12 oz of water and consumed the morning after alcohol consumption.
Study NCT05772975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E-PRF
Description: Platelet-rich fibrin is an autologous biomaterial originating from human blood following centrifugation without additives that contains supraphysiological doses of growth factors. In order to extend its resorption period heating method is used. After centrifugation of blood using (Bio-PRF) centrifuge on 700 g force for 8 minutes top layer is heated for 10 minutes at 75°C in BIO-Heat device. When cooled it is mixed with cell rich buffy coat. This way PRF with extended life is obtained.
Study NCT05105802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention
Description: Using AmDtx MBI-based app, targeted MBI training will consist of a 4-week custom-made program that include, setting intentions and check-in with mood, audio-recorded lectures, guided meditations such as body scans, and writing events journal (Appendix 5). Each standardized course will be unlocked as the child progresses through the program. Users will be encouraged to participate in the app-based activities for a total of 10-15 minutes every day, with a minimum of 4 days in a week, over a period of 4 weeks.
Study NCT05105802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Sham + Usual Care
Description: Usual care recommends that the patient refrain from physical and cognitive activities for 24-48 hours after injury. After the rest period, it is recommended that low to moderate levels of physical and cognitive activity be gradually started 24-48 hours after injury. The activities should be performed at a level that does not result in recurrence or exacerbation of symptoms. Children must refrain from any activities that increase the risk of re-injury (drills with body contact or that risk falls) until fully asymptomatic and cleared by their primary care or other medical provider. The sham journey will consist of playing an open-source cognitive math game delivered through the same app as MBI, but without the mindfulness content.
Study NCT06130046 — intervention group
Intervention type: BIOLOGICAL
Intervention: MR-proADM dosage
Description: Dosage of MR proADM at OLT/KT, 1, 3, 5, 15 POD and 1, 3, 6, 9, 12 months F-U
Study NCT06350929 — intervention group
Intervention type: OTHER
Intervention: Cardiac output monitoring by the Starling™ SV Sebac®
Description: During the surgery, the channels and monitoring equipment will be set up according to the usual procedure in the vascular surgery department. As part of the research, the Starling™ SV Sebac® electrodes will be installed (to measure cardiac flow, cardiac index (CI), stroke volume (VES), variations in stroke volume (VVES), and peripheral resistors (TPRI)).~Once the equipment is in place, anesthetic induction will be carried out according to the usual protocol with curarization and mechanical ventilation.~If the appearance of arterial hypotension is noted after anesthetic induction and mechanical ventilation, the patient will be definitively included in the study. As recommended, he will receive norepinephrine to treat hypotension.~The measurements from the monitoring will be collected at 3, 5, and 10 min after the administration of norepinephrine.~10 days after admission to the operating room, hospitalization data will be collected.
Study NCT05600348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pork Consumption
Description: Feeding of pork is controlled at 0, 3 or 6 oz per day for 4 weeks each in random order.
Study NCT05753722 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRTH-101
Description: PRTH-101 is a humanized immunoglobulin gamma-1 (IgG1) monoclonal antibody
Study NCT05753722 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PRTH-101 in combination with Pembrolizumab
Study NCT05563909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Patients participating in the study will not receive any intervention other than exercise and splint.
Study NCT05563909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wrist Splint
Description: Patients participating in the study will not receive any intervention other than exercise and splint.
Study NCT05563909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wrist Splint
Description: Patients participating in the study will not receive any intervention other than exercise and splint.
Study NCT05563909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Mediated Exercise
Description: Patients participating in the study will not receive any intervention other than exercise and splint.
Study NCT04812366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide 60mg Tab
Description: 4 tablets by mouth once a day for 24 weeks
Study NCT04812366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate 250mg
Description: 4 tablets by mouth on an empty stomach once a day for 16 weeks
Study NCT04812366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone 5mg Tab
Description: 1 tablet by mouth once daily while taking abiraterone acetate
Study NCT04812366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Infusion every 3 weeks for 6 cycles (each cycle has 3 weeks)
Study NCT04812366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niraparib 100mg Oral Capsule
Description: 3 capsules by mouth once daily for 16 weeks
Study NCT04812366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: 1200mg infusion every 3 weeks for 6 cycles
Study NCT04786028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Brand name for interventional drug is Sarclisa
Study NCT06162143 — intervention group
Intervention type: DEVICE
Intervention: Gelsectan®
Description: Gelsectan® is a CE-marked class II device containing xyloglucans, xylo-oligosaccharides, pea proteins, and tannins from grape seeds extract, already used in Irritable Bowel Syndrome (IBS).
Study NCT05746182 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hereditary Cancer Panel
Description: UCSF's Internal Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified Expanded Hereditary Cancer Panel will be employed which measures a minimum 88 genes
Study NCT05086016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheterized Stenting
Description: Catheterized stenting of vascular narrowings.
Study NCT05680337 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS stimulation will occur within 10 minutes. HRV parameters will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.
Study NCT05680337 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS
Description: TENS stimulation will occur within 10 minutes. HRV parameters will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.
Study NCT05383664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultra Violet Light Exposure
Description: Subjects will stand at the determined distance from the UV lamps facing towards them to achieve full body UV exposure. They will stand for the time indicated to achieve the appropriate dose. Each exposure will range from about 1 minute to 4.5 minutes to deliver a dose ranging from 0.22J/cm2 to 0.88J/cm2. Subjects will then rotate to irradiate their back side for the same time to achieve the same dose. On the second visit clinical examination will be conducted for erythema. If no erythema is apparent, the dosage on subsequent visits may increase to the max of 0.88 J/cm2.
Study NCT05774756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Solution for daily subcutaneous injection
Study NCT05774756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to setmelanotide for daily subcutaneous injection
Study NCT06555419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusinersen
Description: Administered as specified in the treatment arm.
Study NCT06555419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThecaFlex DRx System
Description: Implantated as specified in the treatment arm.
Study NCT06639256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product HY07121
Description: HY07121 should be administered intravenously at recommended dose.
Study NCT06490705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tongue resistance exercises, tongue strengthening exercises and tongue resistance exercises
Description: 6 days a week, 3 times a day (before meals), with each session lasting 30 minutes. Don't hold your breath during exercise.~Before conducting the study, all participants received a complete explanation of the purpose, risks, and procedures of the investigation, and provided written informed consent. Procedures were in accordance with the ethical standards of the committee on human experimentation at the institution at which the work was conducted and this study was approved by the Institutional Review Board.
Study NCT03878316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Instranasal Oxytocin
Description: Intranasal Oxytocin - concentrated formulation - 35 IU per dose
Study NCT06490705 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tongue resistance exercises, tongue strengthening exercises and tongue resistance exercises
Description: 6 days a week, 3 times a day (before meals), with each session lasting 30 minutes. Don't hold your breath during exercise.~Before conducting the study, all participants received a complete explanation of the purpose, risks, and procedures of the investigation, and provided written informed consent. Procedures were in accordance with the ethical standards of the committee on human experimentation at the institution at which the work was conducted and this study was approved by the Institutional Review Board.
Study NCT03878316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Instranasal Oxytocin
Description: Intranasal Oxytocin - concentrated formulation - 35 IU per dose
Study NCT05514405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam (Byfavo)
Description: Remimazolam is continuously infused based on bispectral index (within 40-60).
Study NCT05514405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is continuously infused based on bispectral index (within 40-60).
Study NCT05720130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [²¹²Pb]Pb-ADVC001
Description: Ph1b Escalation~Drug: \[²¹²Pb\]Pb-ADVC001administered intravenously per dose escalation scheme~Dose Level 1~- 60 MBq, 4 cycles every 6 weeks~Dose Level 2a~- 120 MBq, 4 to 6 cycles every 4 weeks~Dose Level 2b~- Optional cohort of 120 MBq, 4 to 6 cycles every 2 weeks~Dose Level 3a~- 160 MBq, 4 to 6 cycles every 4 weeks~Dose Level 3b~- Optional cohort of 160 MBq, 4 to 6 cycles every 2 weeks~Dose Level 4a~- 200 MBq, 4 to 6 cycles every 4 weeks~Dose Level 4b~- Optional cohort of 200 MBq, 4 to 6 cycles every 2 weeks~Ph2a Expansion~Drug: \[²¹²Pb\]Pb-ADVC001 at recommended phase 2 dose and schedule
Study NCT04523922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 IU Intranasal Oxytocin
Description: 40 IU Intranasal Oxytocin self administered 30 minutes prior to each COPE session.
Study NCT05197907 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascial release of diaphragm muscle.
Description: The intervention consists of deep tissue massage techniques and manual mobilization of the fascia performed within the diaphragm attachments in the area of the costal arches.
Study NCT05197907 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Classic massage of the abdomen.
Description: The intervention consists of selected classic massage techniques - mainly stroking (effleurage) - performed on the superficial layers of the abdominal region
Study NCT06102629 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy / laparotomy
Description: 1. We will take both blood and ovarian tissue samples used to diagnosis.~2. We will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (surgical profile) before their planned surgery or for disease evaluation.~3. Small tissue samples (from ovary) will be taken from the tissue which is surgically excised as a part of treatment.
Study NCT06102629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NO INTERVENTION
Description: .We will take both blood and ovarian tissue samples used to diagnosis. 2.We will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (surgical profile) before their planned surgery or for disease evaluation.~3. Small tissue samples (from ovary) will be taken from the tissue which is surgically excised as a part of treatment.
Study NCT05478993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD：Selinexor Oral Tablet, Pomalidomide, Dexamethasone
Description: Patients diagnosed with multiple myeloma with CNS involvement to receive Selinexor (60 mg QW), pomalidomide (4 mg/day, on Days 1-21), and dexamethasone (40 mg/day, on Days 1, 8, 15, 22), with all agents dosed 28 days per cycle.~If patients reach maximum efficacy and have received SPD treatment for 8-12 cycles, maintenance treatment of Selinexor (20-60mg QW, optimal dose determined by the investigator) will be started and continued until disease progression or intolerable adverse events.
Study NCT04523922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo (intranasal saline spray) self administered 30 minutes prior to each COPE session.
Study NCT04523922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure
Description: 12 weekly sessions of COPE therapy for PTSD and AUD.
Study NCT04523922 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure
Description: 12 weekly sessions of COPE therapy for PTSD and AUD.
Study NCT05849051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Newly developed warnings with images at 30% size
Description: On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning developed by the study team that includes an image. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
Study NCT05849051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FDA proposed text-only warnings at 30% size
Description: On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning proposed by the FDA which is text only. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
Study NCT04551521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 960 mg twice daily during run-in Phase, followed by 720 mg twice daily
Study NCT04551521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: 60 mg once daily
Study NCT04551521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 840 mg every 2 weeks
Study NCT04551521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg per kilogram of body weight as a loading dose, followed by 6 mg per kilogram every 3 weeks
Study NCT04551521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg as a loading dose, followed by 420 mg intravenously every 3 weeks
Study NCT04551521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: 600 mg twice daily
Study NCT04551521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: 400 mg once daily
Study NCT04551521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg every 3 weeks
Study NCT04551521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg in the first cycle, followed by 840 mg every 3 weeks